Equities

Lotus Pharmaceuticals Inc

LTUS:PKL

Lotus Pharmaceuticals Inc

Actions
  • Price (USD)0.003
  • Today's Change0.00 / 0.00%
  • Shares traded446.10k
  • 1 Year change-50.00%
  • Beta-0.2683
Data delayed at least 15 minutes, as of Jun 04 2024 19:37 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lotus Pharmaceuticals, Inc. (Lotus) develops, manufactures, and sells pharmaceuticals in the China. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Its drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. It operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. (Liang Fang) and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. (En Zhe Jia), collectively Lotus East. Lotus East is engaged in the production, trade and retailing of pharmaceuticals, focusing on the development of medicines and investing in strategic growth to address various medical needs. Lotus East owns and operates 10 drug stores throughout Beijing, China that sell Western and traditional Chinese medications, and generate revenues from the leasing of retail space to third party vendors in its retail stores.

  • Revenue in USD (TTM)70.79m
  • Net income in USD1.72m
  • Incorporated2004
  • Employees233.00
  • Location
    Lotus Pharmaceuticals Inc16 Cheng Zhuang Road, Feng Tai DistrictBEIJING 100071ChinaCHN
  • Phone+86 1 063899868
  • Fax+86 1 063899867
  • Websitehttp://www.lotuspharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kineta Inc5.16m-17.89m7.60m11.00------1.47-1.55-1.550.4673-0.5640.6667----469,181.80-230.51-66.16---86.61-----345.77-854.74--------178.6513.8977.76------
National Graphite Corp0.00-1.97m7.72m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
Twinlab Consolidated Holdings Inc12.65m-9.55m7.77m17.00------0.6146-0.0369-0.05020.0488-0.54471.011.497.30743,941.20-76.13-60.53----34.5921.36-75.51-37.720.0094-0.0108-----20.87-28.58-20.28------
BioRestorative Therapies Inc145.80k-14.42m7.79m11.00--0.4693--53.40-3.54-3.540.03462.450.01--8.2613,254.55-99.26-199.86-104.68-334.04-----9,887.16-19,887.03----0.00--21.705.6122.06--67.77--
Glucose Health Inc1.11m-456.46k7.94m2.00--8.38--7.14-0.033-0.0330.08030.0561-----------86.94---153.9547.1940.68-31.99-56.93313.11--0.00--98.3924.9416.87------
BioCardia Inc468.00k-10.34m8.01m16.00------17.11-0.4692-0.46920.0209-0.08480.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
Lotus Pharmaceuticals Inc70.79m1.72m8.08m233.000.05420.00082.090.11420.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
Cadrenal Therapeutics Inc-100.00bn-100.00bn8.16m3.00------------------------------------------------------------
Endexx Corp4.64m6.93m8.16m--1.21--1.381.760.01330.01330.0091-0.02550.67734.3713.54--86.51------28.73--127.74--0.0664------228.66--28.26------
Cannabis Bioscience Internatnl Hlgs Inc56.94m6.94m8.31m389.000.00150.00020.90030.14590.53280.53284.294.920.591762.811.45146,384.307.83--11.73--31.96--13.24--0.685650.750.0631--12.79--177.84------
Odonate Inc0.00-102.07m8.33m137.00--307.35-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
ABVC Biopharma Inc25.37k-12.62m8.42m16.00--1.07--332.01-2.37-2.370.00430.72840.002--0.06731,585.63-103.15-103.38-189.31-231.54-854.2076.25-51,218.29-2,019.89---3.190.1853---84.2885.3935.97------
Molecular Templates Inc31.76m-18.40m8.56m62.00--1.19--0.2695-4.36-4.365.981.090.6014--19.55512,306.40-34.83-51.78-54.80-73.14-----57.92-228.33---52.110.00--190.1033.9691.24---48.87--
Notable Labs Ltd311.00k-12.39m8.57m16.00--0.7421--27.55-2.31-2.310.06221.280.0142----19,437.50-56.70-52.02-74.10-62.0937.3060.19-3,984.24-3,636.93----0.0271---52.89-11.9365.13---50.69--
Data as of Jun 04 2024. Currency figures normalised to Lotus Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

28.49%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors Ltd.as of 30 Apr 20247.92m28.49%
Data from 06 Jun 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.